The US Food and Drug Administration (FDA) has granted orphan drug designation to Crossject's treatment for status epilepticus (epileptic seizure lasting longer than five minutes), ZENEO Midazolam.
Here, we talk with David Davies, whose appointment as the new head of development at Medherant marks the company’s move into clinical development of the ibuprofen TEPI Patch.
According to the latest figures from the annual Labour Turnover survey, from the manufacturers’ organisation, EEF, the number of people leaving companies rose from 12.3% in 2016 to 13.2% in 2017, although the rate still sits below that of 2015
The industry’s largest survey on serialisation readiness, including data from 660 respondents in the pharma supply chain, has been published by TraceLink.
In a new survey of European and North American companies Mettler Toledo PCE has revealed the importance of serialisation in the fight against counterfeiting.
Biosimilars are increasing in popularity with pharma companies, however, an important consideration for the interested parties is knowing which markets are saturated and which are still open, according to data and analytic company, GlobalData.
As the guidelines for the negotiations of future relations between the EU and the UK are approved, allowing the progression of Brexit talks, pharma, biotech and manufacturing industry leaders give their opinions on the transition.
Growth of $23 billion by the year 2021 is anticipated in the global cholesterol-lowering drugs market, according to a new report from business intelligence provider, Visiongain.
New research from Oracle Health Services in partnership with Informa Engage/Pharma Intelligence has revealed that more than 60% of drug safety experts are planning to use artificial intelligence (AI) to improve the speed and security
This year will be big for Duchenne muscular dystrophy (DMD) as interest in treatments is on the rise and deal activity is increasing, reported data and analytics company, GlobalData.
The Mundipharma network of independent associated companies has expanded its partnership with biopharma company Celltrion Healthcare to now include exclusive distribution rights to trastuzumab biosimilar, Herzuma, in seven EU markets.
According to data and analytics company, GlobalData, new real-world evidence will support the use of a biosimilar treatment for Crohn’s disease (CD), leading to a boost in the biosimilar market value.
